Metformin × cardiac & vascular function

TrialDiabetes, obesity & metabolism2017

Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.

John R Petrie et al.PubMed ↗Full text ↗Publisher ↗

  • Metforminno clear effectHigher progression of averaged mean far wall common carotid intima-media thickness, no range given.No ranges given.

What the trial testedas reported · 500 people · 2017

No range given

Reported higher progression of averaged mean far wall common carotid intima-media thickness, no range given

+0.02

metformin vs placebo

As reported

difference 0.0167, no interval

Who was studied, and how

500people with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

metformin
placebo

Reported higher progression of averaged mean far wall common carotid intima-media thickness, no range given+0.02

randomised

the abstract, start to end

90% power to detect a mean difference of 0.0167 mm in cIMT progression between

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Progression of averaged mean far wall common carotid intima-media thickness (cIMT)metformin vs placebo
0.0167
MetforminCardiac & vascular function
1 / 4

22 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 27935183